background image

Paid Clinical Trials Chattanooga

Discover 127 paid clinical trials in Chattanooga, Tennessee. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.

Filter
2
Active & Responsive

A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)

for
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Location: 40 recruiting locations
Sponsor: Merck Sharp & Dohme LLC

Sex: All

Age: 18+

Code: NCT06136559

Phase3, Recruiting
Active & Responsive

Esprit BTK Post-Approval Study

for
Chronic Limb-Threatening Ischemia
Location: 28 recruiting locations
Sponsor: Abbott Medical Devices

Sex: All

Age: 18+

Code: NCT06656364

Recruiting
Active & Responsive

Innovative Automated Insulin Delivery System for Type 2 Diabetes

for
Type 2 Diabetes, Insulin Treated Type 2 Diabetes Mellitus
Location: 27 recruiting locations
Sponsor: Deka Research and Development

Sex: All

Age: 18+

Code: NCT06853990

Recruiting
Active & Responsive

Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC

for
Breast Cancer, Triple Negative Breast Cancer, PD-L1 Negative
Location: 12 recruiting locations
Sponsor: Dana-Farber Cancer Institute

Sex: All

Age: 18+

Code: NCT04468061

Phase2, Recruiting
Active & Responsive

A Study of Dostarlimab vs Placebo After Chemoradiation in Adult Participants With Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma

for
Neoplasms, Head and Neck
Location: 28 recruiting locations
Sponsor: GlaxoSmithKline

Sex: All

Age: 18+

Code: NCT06256588

Phase3, Recruiting

Interested in new trials?

Get alerts for new trials in your area by subscribing now

Subscriber Image
Active & Responsive

A Study to Evaluate the Optimization of the Cytokine Release Syndrome Profile for Glofitamab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed/Refractory Diffuse Large B-Cell Lymphoma

for
Diffuse Large B-Cell Lymphoma
Location: 30 recruiting locations
Sponsor: Hoffmann-La Roche

Sex: All

Age: 18+

Code: NCT06806033

Phase2, Recruiting
Active & Responsive

Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)

for
Platinum-resistant Ovarian Cancer,
Location: 29 recruiting locations
Sponsor: Genelux Corporation

Sex: Female

Age: 18+

Code: NCT05281471

Phase3, Recruiting
Active & Responsive

A Study Evaluating Efruxifermin in Subjects With Non-Cirrhotic Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Fibrosis

for
NASH With Fibrosis, MASH With Fibrosis
Location: 143 recruiting locations
Sponsor: Akero Therapeutics, Inc

Sex: All

Age: 18 - 70+

Code: NCT06215716

Phase3, Recruiting
Active & Responsive

AlloNK®, an Allogeneic Non-genetically Modified, Cord Blood-derived NK Cell Therapy, in Combination With Rituximab, Studied in Relapsing Forms of B-cell Dependent Rheumatologic Diseases.

for
Refractory Rheumatoid Arthritis (RA),
Location: 12 recruiting locations
Sponsor: Artiva Biotherapeutics, Inc.

Sex: All

Age: 18+

Code: NCT06991114

Phase2, Recruiting
Active & Responsive

A Randomized Comparison of Stage-Based Care Versus Risk Factor-Based Care for Prevention of Cardiovascular Events

for
Diabetes Mellitus, Type 2, PreDiabetes, Metabolic Syndrome
Location: 89 recruiting locations
Sponsor: Cleerly, Inc.

Sex: All

Age: 55+

Code: NCT06112418

Recruiting